Promoter holding
64.27%
SP
Sudarshan Pharma Industries Limited - Due diligence report
A 360° intelligence report on Sudarshan Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signa…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Sudarshan Pharma — 360° Intelligence Report
Generated from MCA filings & public records69/100
Trust Score
Moderate
Sudarshan Pharma is assessed as Moderate with a Trust Score of 69/100. Sudarshan Pharma is an active public limited indian non-government company incorporated in 2008, operating in the Professional Services sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Sudarshan Pharma Industries Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
69/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
63/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
30/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
40/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 30/100 Caution Indicated
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Elevated gearing (D/E 1.42).
- Profitable - internal accruals available.
Charges position: 17 open (254.91 cr) · 5 satisfied (24.85 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 13 | 48.0 cr |
| Axis Bank Limited | 3 | 48.0 cr |
| Indian Bank | 1 | 48.0 cr |
| Tata Capital Financial Services Limited | 2 | 48.0 cr |
| Hdfc Bank Limited | 2 | 48.0 cr |
| Deutsche Bank Ag | 1 | 48.0 cr |
Compliance Score: 63/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 1 court forum(s).
- 1 auditor resignation(s) filed - latest: DHARMESH MUNI & CO on 2018-08-01.
- Delayed payments to MSME suppliers disclosed (33 disclosure(s)).
- 4 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 40/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| JAYA ANKUR SINGHANIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIJAY OJHA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RUSHABH PRASHANT PATIL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HEMAL VASANTRAI MEHTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SACHIN VASANTRAI MEHTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NIRAV KISHOR SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANIL BALKRISHNA GHOGARE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Manoj Lalchand Lodha | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Nirav Kishor Shah | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 9 directors on the board.
- VIJAY OJHA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 3 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
3
Group entities
3
Capital events
10 allotment(s) · 0 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Life Science Chemical Private Limited | Subsidiary Company | 74.00% |
| Ratna Lifesciences Private Limited | Subsidiary Company | 74.00% |
| Sudarshan Pharma Lifescience Private Limited | Subsidiary Company | 74.00% |
Key managerial personnel: HEMAL VASANTRAI MEHTA (Managing Director) · SACHIN VASANTRAI MEHTA (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
EPFO headcount growing - hiring signal.
Operating for 17+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 38% in a year.
17 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 75.86 Lakh.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence70/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment50/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 17 open charge(s) of 254.91 cr already registered.
- Compliance gaps should be priced into terms.
Investor view80/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 5 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events18 Oct 2025
Director appointed
VIJAY OJHA (Additional Director)
05 Aug 2025
Director ceased
MANOJ LALCHAND LODHA
24 May 2025
Director appointed
Manoj Lalchand Lodha (Cfo)
05 May 2025
Charge created
Indian Bank - 30.00 cr
26 Dec 2024
Charge created
Others - 48.00 cr
21 Nov 2024
Charge created
Others - 3.03 cr
30 Sep 2024
Last AGM held
Annual general meeting
29 Jul 2024
Charge created
Hdfc Bank Limited - 80.48 Lakh
22 Jun 2024
Director appointed
Nirav Kishor Shah (Company Secretary)
12 Jun 2024
Charge satisfied
Others
01 Jun 2024
Director appointed
NIRAV KISHOR SHAH (Company Secretary)
13 May 2024
Charge created
Others - 5.00 cr
31 Mar 2024
Latest balance sheet
Filed with ROC
28 Mar 2024
Charge created
Others - 46.50 cr
04 Feb 2024
Director ceased
ANIL BALKRISHNA GHOGARE
10
Key Observations
Auto-generated from the data aboveRevenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - leverage worth monitoring.
Net worth is positive.
9 active director(s) / partner(s); review board churn before relying on management continuity.
4 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 3 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 10 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Shrihari Coal & Power Private Limited | U10100MH2009PTC194542 | Nagpur, Maharashtra, India |
| Ahp Garments Private Limited | U18109DL2012PTC237474 | New Delhi, Delhi, India |
| Superon Schweisstechnik Industries Limited | U29100DL2022PLC392689 | New Delhi, Delhi, India |
| Nutrilite Agro Products Private Limited | U15132DL2011PTC216877 | Delhi, Delhi, India |
| Sudarshan Pharma | L51496MH2008PLC184997 | Mumbai, Maharashtra, India |
| Hv Connecting Infra (India) Private Limited | U01403GJ2008PTC052740 | Surat, Gujarat, India |
| Govind Agrofin Private Limited | U01100RJ2012PTC039956 | Jodhpur, Rajasthan, India |
| Mahesh Hardware & Pipes Private Limited | U25209KA2009PTC049271 | Bangalore, Karnataka, India |
| Lahoti Overseas Limited | L74999MH1995PLC087643 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Sudarshan Pharma before audits and certifications: compliance score 63/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Sudarshan Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 30/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Sudarshan Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 69/100, distress signals and MSME payment-delay disclosures - know whether Sudarshan Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Sudarshan Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Sudarshan Pharma an active company?
Sudarshan Pharma has MCA status “Active” with a compliance score of 63/100 (Moderate).
Is Sudarshan Pharma financially healthy?
Sudarshan Pharma has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.
Should I do business with Sudarshan Pharma?
Its overall Trust Score is 69/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Sudarshan Pharma?
Promoters hold a minority stake - exact percentages are in the full report. 9 active director(s) are on record.
Does Sudarshan Pharma have loans or charges against its assets?
17 open charge(s) are registered against its assets, and 5 earlier charge(s) stand satisfied.
Is Sudarshan Pharma up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 63/100 (Moderate).
Is it risky to lend to Sudarshan Pharma?
Its Credit Risk Score is 30/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
